Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Monoclonal and Polyclonal Antibodies Research, and Cancer Treatment and Pharmacology.
Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers.
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ <i>ERBB2</i> -Negative Early Breast Cancer
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.
Supplementary Figures from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Table 1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Supplemental Table 2 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Supplemental Table 4 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Table 3 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplementary Tables from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Data from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplementary Data 1 from Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Data from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Methods 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Data from Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.